Drug Profile
Research programme: bacterial and viral vaccines - Berna Biotech/Hesperion
Alternative Names: Vaccines research programme - Berna Biotech/HesperionLatest Information Update: 04 Jun 2007
Price :
$50
*
At a glance
- Originator Berna Biotech
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections; Viral infections
Most Recent Events
- 25 Mar 2004 Hesperion has been acquired by Cerep
- 05 Feb 2003 Preclinical trials in Bacterial infections in Switzerland (unspecified route)
- 05 Feb 2003 Preclinical trials in Viral infections in Switzerland (unspecified route)